Assistance Publique – Hôpitaux de Paris

Running trials

• Not yet recruiting

  A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

  NCT07335562· Phase 3· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Not yet recruiting

  Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative Colitis

  NCT07718529· Phase 4· Assistance Publique Hopitaux De Marseille· Source

• Not yet recruiting

  Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations

  NCT07738887· Phase 2· The Lymphoma Academic Research Organisation· Source

• Not yet recruiting

  Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

  NCT07441408· Phase 3· Bristol-Myers Squibb· Source

• Not yet recruiting

  Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis

  2025-523400-72-00· Phase 2· Vertex Pharmaceuticals Inc.· Source

• Not yet recruiting

  A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma

  NCT07612787· Phase 1/2· Centre Hospitalier Universitaire de Saint Etienne· Source

• Not yet recruiting

  Evaluation of the Effect of Time of Administration on the Activity on First Line of Pembrolizumab in Association With Carboplatin-pemetrexed in Metastatic Non-squamous Lung Cancer. A Randomised Multicenter Phase III Trial

  NCT07915037· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial

  NCT07576452· Phase 4· University Hospital, Clermont-Ferrand· Source

• Not yet recruiting

  Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis

  NCT06390436· Phase 4· Centre Hospitalier Universitaire de Saint Etienne· Source

• Not yet recruiting

  A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis

  2026-526404-71-00· Phase 2· Agomab Spain S.L.U.· Source

• Not yet recruiting

  A trial to learn how well Dato-DXd works and how safe it is with other anticancer drugs in adults with TROP2 NMR-positive non-small cell lung cancer

  2025-524836-21-00· Phase 2· AstraZeneca AB· Source

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

  NCT07781657· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease

  NCT07781644· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  2024-518365-10-00· Phase 3· F. Hoffmann-La Roche AG· Source

• Not yet recruiting

  A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)

  2026-525757-37-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Not yet recruiting

  A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)

  2026-525755-82-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Recruiting

  Phase I/II Clinical Study to Assess the Safety, Efficacy and Select the Dose of NFL-102 as a Tobacco and Nicotine Cessation Therapy (TONIC trial)

  2026-527266-77-00· Phase 1/2· Nfl Biosciences· Source

• Not yet recruiting

  A Phase 2, open-label trial to investigate the long-term safety of VO659 administered intrathecally in participants with Huntington’s disease and spinocerebellar ataxia type 1 and 3

  2026-526408-60-00· Phase 2· Vico Therapeutics B.V.· Source

• Recruiting

  Study to assess the safety, tolerability, and effects of vortosiran in two groups: participants who previously had a blood clot and completed initial blood-thinner treatment, and participants with cancer who are at high risk of blood clots

  2026-525479-15-00· Phase 2· Ribocure Pharmaceuticals AB· Source

• Not yet recruiting

  Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung Cancer

  NCT07759492· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source

• Not yet recruiting

  A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis

  NCT07873801· Phase 3· Almirall, S.A.· Source

• Recruiting

  Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes

  NCT07672769· Phase 2· Faron Pharmaceuticals Ltd· Source

• Not yet recruiting

  VItiligo RegisTry adUlts And chiLdren-France

  NCT07927699· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment. (EQUILIBRIUM-ADCS)

  2025-522648-42-01· Phase 2/3· Crinetics Pharmaceuticals Inc.· Source

• Recruiting

  Evaluation of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

  2025-523288-39-00· Phase 2· Mediar Therapeutics Inc.· Source

• Recruiting

  A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease

  2026-525197-19-00· Phase 2· Agomab Spain S.L.U.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia

  NCT07778836· Phase 3· Larimar Therapeutics, Inc.· Source

• Not yet recruiting

  Comparative Study of Two Vaccination Schedules for the Subunit Herpes Zoster Vaccine in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disease Patients Treated With Anti-CD20 Therapy: an Open-label Randomised Controlled Trial

  NCT07818356· Phase 4· University Hospital, Toulouse· Source

• Recruiting

  A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A

  NCT07830732· Phase 3· Novo Nordisk A/S· Source

• Not yet recruiting

  Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of Bimekizumab

  NCT07836283· Phase 3· University Hospital, Rouen· Source

• Recruiting

  A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE).

  2026-526139-20-00· Phase 3· Kardigan Inc.· Source

• Recruiting

  Phase 3 Study of Investigator Choice of Chemotherapy with or without Zoldonrasib as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma

  2025-524928-21-00· Phase 3· Revolution Medicines Inc.· Source

• Not yet recruiting

  Tenecteplase for the treatment of acute stroke in the late time window before inter-hospital transfer for thrombectomy: a randomized controlled trial

  2026-525280-40-00· Phase 3· Fondation A De Rothschild· Source

• Not yet recruiting

  Use of Low Doses of Interleukin-2 in Autism Spectrum Disorders

  NCT07589842· Phase 2· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  A Study to Investigate the Effects of Cleminorexton Compared with Placebo in the Treatment of Participants with Central Disorders of Hypersomnolence

  2026-525961-37-00· Phase 2/3· Centessa Pharmaceuticals UK Limited· Source

• Not yet recruiting

  Evaluate the superiority of Treatment with RAvulizumab vs plasma exchange during the first episode or a relapse In acute neuromyelitis optica (NMO) patients: a national, multicentric, randomised trial

  2026-526632-39-00· Phase 3· Les Hopitaux Universitaires De Strasbourg· Source

• Enrolling by invitation

  Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France

  NCT07729852· Phase 2· Alterity Therapeutics· Source

• Not yet recruiting

  ACetazolamide in Patients With Heart Failure, to Decrease Weight and relIEVE Symptoms.

  NCT07737964· Phase 3· University Hospital, Montpellier· Source

• Recruiting

  Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)

  NCT07441200· Phase 2· NS Pharma, Inc.· Source

• Recruiting

  Methotrexate Treatment in Hand Osteoarthritis Refractory to Usual Treatments

  NCT07501507· Phase 2/3· Centre Hospitalier Universitaire de Nice· Source

• Recruiting

  ROSY-F: Roll-over Study for Participants Who Have Completed a Previous Clinical Study with Benralizumab (Fasenra) and Benefit from Continued Treatment

  2025-523307-29-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

  2026-526654-14-01· Phase 3· Janssen Cilag International· Source

• Recruiting

  Evaluating Aganirsen Eye Drops to Reduce the Number of Aflibercept Injections in Wet Age-Related Macular Degeneration Patients.

  2026-526775-27-00· Phase 2· Laboratoires Kol· Source

• Not yet recruiting

  Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

  NCT07420439· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source

• Recruiting

  Feasibility of the Application of a new Six-month Treatment for multidrug-resistant tuberculosis (MDR-TB) patients in France (FAST-MDR)

  2024-512763-32-00· Phase 3· Assistance Publique Hopitaux De Paris· Source

• Recruiting

  A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· Phase 3· Takeda· Source

• Recruiting

  A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT07680764· Phase 2· Bristol-Myers Squibb· Source

• Recruiting

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· Phase 3· Incyte Corp.· Source

• Recruiting

  Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

  NCT07680790· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

  2025-525016-41-00· Phase 2· AstraZeneca AB· Source

Showing 50 of 897.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer50 recruiting
• Colorectal cancer46 recruiting
• Multiple myeloma32 recruiting
• Fatty liver disease (MASLD/MASH)28 recruiting
• Crohn's disease27 recruiting
• Lupus (SLE)27 recruiting
• Childhood cancers26 recruiting
• High blood pressure25 recruiting
• Systemic sclerosis (scleroderma)25 recruiting
• ANCA-associated vasculitis23 recruiting
• Acute myeloid leukaemia22 recruiting
• Heart failure19 recruiting
• Prostate cancer19 recruiting
• Stroke19 recruiting
• Asthma18 recruiting
• Idiopathic pulmonary fibrosis18 recruiting
• Rheumatoid arthritis18 recruiting
• Sickle cell disease18 recruiting
• Bladder cancer17 recruiting
• HIV17 recruiting
• Liver and biliary tract cancer17 recruiting
• Multiple sclerosis17 recruiting
• Pancreatic cancer17 recruiting
• Acute lymphoblastic leukaemia15 recruiting
• Myocarditis14 recruiting
• Pulmonary arterial hypertension14 recruiting
• Sarcoidosis13 recruiting
• Haemophagocytic lymphohistiocytosis12 recruiting
• Myelodysplastic syndromes12 recruiting
• Liver cirrhosis11 recruiting
• Dermatomyositis and polymyositis (myositis)10 recruiting
• Metastatic breast cancer10 recruiting
• Type 2 diabetes10 recruiting
• Ulcerative colitis10 recruiting
• Chronic kidney disease9 recruiting
• Gastric and oesophageal cancer9 recruiting
• Kidney cancer9 recruiting
• Osteoarthritis9 recruiting
• Bronchiectasis8 recruiting
• Cystic fibrosis8 recruiting
• Diffuse large B-cell lymphoma8 recruiting
• IgA nephropathy8 recruiting
• Melanoma8 recruiting
• Obesity8 recruiting
• Sjögren's disease8 recruiting
• Alzheimer disease7 recruiting
• Chronic lymphocytic leukaemia7 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)7 recruiting
• Coronary artery disease7 recruiting
• Follicular lymphoma7 recruiting
• Huntington's disease7 recruiting
• Myasthenia gravis7 recruiting
• Parkinson disease7 recruiting
• Primary biliary cholangitis7 recruiting
• Tuberculosis7 recruiting
• Amyloidosis6 recruiting
• Aortic stenosis6 recruiting
• Deep vein thrombosis and pulmonary embolism6 recruiting
• Endometrial cancer6 recruiting
• Glioblastoma6 recruiting
• Head and neck cancer6 recruiting
• Macular degeneration6 recruiting
• Mantle cell lymphoma6 recruiting
• Myotonic dystrophy6 recruiting
• Cushing's syndrome5 recruiting
• Gout5 recruiting
• Hodgkin lymphoma5 recruiting
• Myeloproliferative neoplasms5 recruiting
• Neuromyelitis optica (NMOSD)5 recruiting
• Ovarian cancer5 recruiting
• Sarcoma5 recruiting
• Type 1 diabetes5 recruiting
• ALS (motor neurone disease)4 recruiting
• Ankylosing spondylitis4 recruiting
• Cytomegalovirus infection4 recruiting
• Immune thrombocytopenia (ITP)4 recruiting
• Lewy body dementia4 recruiting
• Mitochondrial disease4 recruiting
• Narcolepsy4 recruiting
• Psoriasis4 recruiting
• Atopic dermatitis (eczema)3 recruiting
• Chronic myeloid leukaemia3 recruiting
• COPD3 recruiting
• Diabetic eye disease3 recruiting
• Duchenne muscular dystrophy3 recruiting
• Epilepsy3 recruiting
• Giant cell arteritis3 recruiting
• Haemophilia3 recruiting
• Hearing loss3 recruiting
• Hypertrophic cardiomyopathy3 recruiting
• Iron deficiency anaemia3 recruiting
• Polymyalgia rheumatica3 recruiting
• Vitiligo3 recruiting
• Autism2 recruiting
• Chronic spontaneous urticaria2 recruiting
• Dilated cardiomyopathy2 recruiting
• Epidermolysis bullosa2 recruiting
• Friedreich ataxia2 recruiting
• Hidradenitis suppurativa2 recruiting
• Insomnia2 recruiting
• Irritable bowel syndrome2 recruiting
• Meningioma2 recruiting
• Multiple system atrophy2 recruiting
• Osteoporosis2 recruiting
• Spinal muscular atrophy2 recruiting
• Thalassaemia2 recruiting
• Triple-negative breast cancer2 recruiting
• Turner syndrome2 recruiting
• Atrial fibrillation1 recruiting
• Burkitt lymphoma1 recruiting
• Cerebral palsy1 recruiting
• Cervical cancer1 recruiting
• Depression1 recruiting
• Diabetic foot ulcer1 recruiting
• Diabetic neuropathy1 recruiting
• Mild cognitive impairment1 recruiting
• Neuroendocrine tumours1 recruiting
• Peripheral artery disease1 recruiting
• Psoriatic arthritis1 recruiting
• Schizophrenia1 recruiting
• Thyroid cancer1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Not yet recruiting

  Phase 2 Trial of TAK-755 for Acute Ischemic Stroke

  2025-522734-31-00· Phase 2· Takeda Development Center Americas Inc.· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

  NCT07564141· Phase 3· Genmab· Source

• Recruiting

  Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

  2025-524335-39-00· Phase 3· Gilead Sciences Inc.· Source

• Recruiting

  A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.

  NCT07596849· Phase 3· argenx· Source

• Completed

  Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults with Advanced Colorectal Cancer.

  2025-523984-39-00· Phase 2· Gilead Sciences Inc.· Source

• Completed

  A Phase 2 Study of Petosemtamab in Combination with Pembrolizumab in Adults with NSCLC

  2025-522867-13-00· Phase 2· Merus B.V.· Source

• Completed

  A Phase I Study of BMS-986497 alone or in combination with Azacitidine (Aza) and Azacitidine plus Venetoclax (AZA+VEN) in relapsed or refractory (R/R) AML or MDS

  2024-519537-29-00· Phase 1· Bristol-Myers Squibb Services Unlimited Company· Source

• Completed

  A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease

  2024-516966-12-00· Phase 2· Novartis Pharma AG· Source

• Terminated

  A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants

  NCT07218770· Phase 1/2· Regeneron Pharmaceuticals· Source

• Completed

  PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1) in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma with progression during or after peri-operative chemotherapy.

  2024-519258-35-00· Phase 2· Fondation Franc.Cancerologie Digestive· Source

• Active, not recruiting

  A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

  NCT07288203· Phase 2· Iovance Biotherapeutics, Inc.· Source

• Completed

  GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease.

  2025-521107-42-00· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Terminated

  Effects of Yoghurt Consumption on Glucose Metabolism in Prediabetic Subjects

  NCT06836752· Danone Global Research & Innovation Center· Source

• Recruiting

  Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)

  NCT07048262· Phase 2· CSL Behring· Source

• Not yet recruiting

  Evaluation of Efficacy and Safety De-escalation Versus Standard Adjuvant Chemotherapy in Patients With Low Risk Localized Gastroesophageal Adenocarcinoma

  NCT06933966· Phase 2· Centre Leon Berard· Source

• Terminated

  A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy

  NCT06987968· Phase 2· Genfit· Source

• Completed

  Phase 2b Randomized, Double-Blind Study with Phage for CF Subjects with Pseudomonas Lung Infection

  2024-519856-94-00· Phase 2· Biomx Ltd.· Source

• Recruiting

  A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

  NCT06948318· Phase 3· Takeda· Source

• Completed

  A multicentre, randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of BP1.4979 in adult patients with essential tremor

  2024-517987-46-00· Phase 2· Bioprojet Pharma· Source

• Recruiting

  Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

  NCT06699849· Phase 2· CSL Behring· Source

• Completed

  A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis

  NCT07225829· Phase 2· 4Moving Biotech· Source

• Recruiting

  Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Pancreatic Cancer (Substudy PDAC)

  2024-517819-74-00· Phase 1/2· Merck Healthcare KGaA· Source

• Completed

  A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY)

  NCT06684847· Phase 3· Argenx· Source

• Completed

  A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis

  2023-507771-22-01· Phase 3· Intercept Pharmaceuticals Inc.· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

  NCT06863961· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

  NCT06722235· Phase 3· Takeda· Source

• Active, not recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

  NCT06744920· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

  NCT06797869· Phase 2· Novo Nordisk A/S· Source

• Active, not recruiting

  A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

  NCT06593522· Phase 2· Amgen· Source

• Active, not recruiting

  A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis

  NCT07667322· Phase 1· Hoffmann-La Roche· Source

• Terminated

  A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)

  NCT06685835· Phase 2· Insmed Incorporated· Source

• Active, not recruiting

  ​Clinical trial of patritumab deruxtecan in people with gastrointestinal cancers​

  2024-512442-41-00· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis

  NCT06444113· Phase 4· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

  NCT06422884· Phase 2· Endeavor Biomedicines, Inc.· Source

• Active, not recruiting

  A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

  NCT06614192· Phase 2· AbbVie· Source

• Completed

  A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart in Participants with Sjögren’s Disease

  2024-512986-15-00· Phase 2· Kiniksa Pharmaceuticals GmbH· Source

• Completed

  A study to investigate the safety and pharmacological effect of a single intravenous infusion of GSK2857914 in male and female participants aged 18 to 75 with moderate to severe systemic lupus erythematosus

  NCT06413511· Phase 1· Glaxosmithkline Research & Development Limited· Source

• Completed

  Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

  NCT06433219· Phase 2· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

  NCT06815965· Phase 2· EIP Pharma Inc· Source

• Completed

  Effect of Copper CU64 PSMA I&T scanning to detect potential disease spread to lymph nodes in men with newly diagnosed Prostate Cancer

  2024-512754-16-01· Phase 3· Curium US LLC· Source

• Completed

  A Study of TAK-861 in People With Narcolepsy Type 1

  NCT06505031· Phase 3· Takeda· Source

• Recruiting

  Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

  NCT06333808· Phase 3· Gilead Sciences Inc.· Source

• Completed

  A Clinical Study of Mitapivat in Patients with Sickle Cell Disease and Kidney Disease

  NCT06286046· Phase 2· Agios Pharmaceuticals Inc.· Source

• Completed

  Phase 2 study to evaluate the efficacy and safety of GSK3915393 in participants with Idiopathic Pulmonary Fibrosis (IPF)

  NCT06317285· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Active, not recruiting

  To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

  NCT06553027· Phase 3· Cerevance· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa

  NCT06603077· Phase 2· Avalo Therapeutics, Inc.· Source

• Completed

  A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis

  2023-510249-79-00· Phase 2· Boehringer Ingelheim International GmbH· Source

• Active, not recruiting

  A clinical trial to be conducted in many hospitals and in different countries with the medicinal substance Regadenoson to be used in a type of heart scan called 'radionuclide myocardial perfusion imaging' to see the blood flow in the heart muscle in patients aged between 1 month - 18 years.

  2024-515244-22-00· Phase 1/2· GE Healthcare Limited· Source

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Boehringer Ingelheim· Source

• Completed

  A study to see how safe and effective the drug Luveltamab Tazevibulin (STRO-002) is in treating infants and children under 12 years old with a specific type of acute myeloid leukemia (AML)

  2023-506240-16-00· Phase 1/2· Sutro Biopharma Inc.· Source

Showing 50 of 368.

Conditions

Diseases this institution publishes on or runs trials for.

• Stroke214 works · 18 trials
• Liver and biliary tract cancer170 works · 35 trials
• Heart failure168 works · 14 trials
• HIV167 works · 25 trials
• Obesity161 works · 11 trials
• Deep vein thrombosis and pulmonary embolism99 works · 6 trials
• Lung cancer97 works · 105 trials
• Chronic kidney disease89 works · 12 trials
• Pulmonary arterial hypertension78 works · 23 trials
• Colorectal cancer77 works · 54 trials
• Epilepsy75 works · 4 trials
• Crohn's disease72 works · 21 trials
• Asthma69 works · 16 trials
• Parkinson disease68 works · 10 trials
• Type 2 diabetes68 works · 13 trials
• Bladder cancer67 works · 28 trials
• Atrial fibrillation66 works · 3 trials
• Rheumatoid arthritis63 works · 11 trials
• Melanoma63 works · 26 trials
• Cystic fibrosis60 works · 13 trials
• Multiple sclerosis56 works · 24 trials
• Sickle cell disease54 works · 15 trials
• Lupus (SLE)51 works · 25 trials
• Acute myeloid leukaemia50 works · 35 trials
• Osteoarthritis49 works · 7 trials
• Tuberculosis48 works · 2 trials
• Myocarditis46 works · 6 trials
• Psoriasis45 works · 6 trials
• Coronary artery disease44 works · 6 trials
• Amyloidosis43 works · 10 trials